ValuEngine upgraded shares of Acasti Pharma, Inc. (NASDAQ:ACST) from a sell rating to a hold rating in a report issued on Monday.

Shares of Acasti Pharma (NASDAQ:ACST) opened at $3.10 on Monday. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.55 and a quick ratio of 4.55. Acasti Pharma has a 12-month low of $1.11 and a 12-month high of $3.36.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark laws. The legal version of this piece of content can be accessed at

About Acasti Pharma

Acasti Pharma Inc is a Canada-based biopharmaceutical company. The Company is focused on the research, development and commercialization of prescription drugs using omega 3 fatty acids (OM3s) derived from krill oil. OM3s has clinical evidence of safety and efficacy in lowering triglycerides in patients with hypertriglyceridemia (HTG).

Receive News & Stock Ratings for Acasti Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acasti Pharma Inc. and related stocks with our FREE daily email newsletter.